Journal of Drug Targeting最新文献_第4页

S-nitrosoglutathione releasing nano-micron combination hydrogel enhances cutaneous wound healing via promoting angiogenesis and collagen deposition. s -亚硝基谷胱甘肽释放纳米复合水凝胶通过促进血管生成和胶原沉积促进皮肤伤口愈合。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-04-16 DOI: 10.1080/1061186X.2025.2489983

Ying Fan, Chuli Liao, Jie Li, Meiling Wu, Jie Liu, Feng Li, Wen Wu

{"title":"S-nitrosoglutathione releasing nano-micron combination hydrogel enhances cutaneous wound healing via promoting angiogenesis and collagen deposition.","authors":"Ying Fan, Chuli Liao, Jie Li, Meiling Wu, Jie Liu, Feng Li, Wen Wu","doi":"10.1080/1061186X.2025.2489983","DOIUrl":"10.1080/1061186X.2025.2489983","url":null,"abstract":"Nitric oxide (NO) is essential for wound healing, promoting angiogenesis and collagen deposition. This study investigates a novel dual-matrix nanocomposite hydrogel incorporating S-nitrosoglutathione (GSNO), a physiological NO donor, to enhance cutaneous wound healing. GSNO was encapsulated in ammonio methacrylate copolymer nanoparticles and embedded in an alginate-based matrix, achieving controlled NO release. GSNO-loaded nanoparticles were prepared using solvent displacement and solvent evaporation methods, resulting in spherical, well-distributed and positively charged particles. These nanoparticles were cross-linked with negatively charged alginic acid to form a nanocomposite hydrogel. The hydrophobic nanoparticles protected GSNO from degradation, while the hydrophilic alginate matrix sustained the release of active GSNO for up to 10 h, promoting haemostasis and maintaining a moist wound environment. The hydrogel exhibited good biocompatibility in human fibroblasts and significantly enhanced wound repair by promoting fibroblast formation, neovascularisation and collagen deposition, as demonstrated by haematoxylin and eosin staining and Masson's trichrome staining. In conclusion, the GSNO-loaded nanocomposite hydrogel significantly accelerated the healing process by enhancing angiogenesis and collagen deposition, offering a promising strategy for improving wound healing.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1412-1420"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential use of bacteria and their derivatives as delivery systems for nanoparticles in the treatment of cancer. 细菌及其衍生物作为纳米颗粒递送系统在癌症治疗中的潜在用途。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-04-12 DOI: 10.1080/1061186X.2025.2489979

Shiva Ahmadishoar, Samaa Mones Saeed, Morug Salih Mahdi, Waam Mohammed Taher, Mariem Alwan, Mahmod Jasem Jawad, Atheer Khdyair Hamad, Hossein Gandomkar

{"title":"The potential use of bacteria and their derivatives as delivery systems for nanoparticles in the treatment of cancer.","authors":"Shiva Ahmadishoar, Samaa Mones Saeed, Morug Salih Mahdi, Waam Mohammed Taher, Mariem Alwan, Mahmod Jasem Jawad, Atheer Khdyair Hamad, Hossein Gandomkar","doi":"10.1080/1061186X.2025.2489979","DOIUrl":"10.1080/1061186X.2025.2489979","url":null,"abstract":"Cancer is a leading cause of mortality and morbidity worldwide. Nanomaterials, unique optical, magnetic, and electrical properties at the nanoscale (1-100 nm), have been engineered to improve drug capacity, bioavailability, and specificity in cancer treatment. These advancements address toxicity and lack of selectivity in conventional therapies, enabling precise targeting of cancer cells, the tumour microenvironment, and the immune system. Among emerging approaches, bacterial treatment shows promise due to its natural ability to target cancer and its diverse therapeutic mechanisms, which nanotechnology can further enhance. Bacteria-based drug delivery systems leverage bacteria's adaptability and survival strategies within the human body. Bacterial derivatives, such as bacterial ghosts (BGs), bacterial extracellular vesicles (BEVs), and dietary toxins, are recognised as effective biological nanomaterials capable of carrying nanoparticles (NPs). These systems have attracted increasing attention for their potential in targeted NP delivery for cancer treatment. This study explores the use of various bacteria and their byproducts as NP delivery vehicles, highlighting their potential in treating different types of cancer. By combining the strengths of nanotechnology and bacterial therapy, these innovative approaches aim to revolutionise cancer treatment with improved precision and efficacy.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1272-1305"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hedgehog signalling pathway inhibitors in the treatment of basal cell carcinoma: an updated review. 刺猬信号通路抑制剂治疗基底细胞癌：最新综述

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-05-07 DOI: 10.1080/1061186X.2025.2496470

Adela Markota Cagalj, Mislav Glibo, Valentina Karin-Kujundzic, Alan Serman, Semir Vranic, Ljiljana Serman, Lucija Skara Abramovic, Zrinka Bukvic Mokos

{"title":"Hedgehog signalling pathway inhibitors in the treatment of basal cell carcinoma: an updated review.","authors":"Adela Markota Cagalj, Mislav Glibo, Valentina Karin-Kujundzic, Alan Serman, Semir Vranic, Ljiljana Serman, Lucija Skara Abramovic, Zrinka Bukvic Mokos","doi":"10.1080/1061186X.2025.2496470","DOIUrl":"10.1080/1061186X.2025.2496470","url":null,"abstract":"Basal cell carcinoma (BCC) is the most common type of skin cancer that usually appears in sun-exposed body regions such as the head, trunk, and extremities. There are four main clinicopathological subtypes of BCC: nodular, superficial, morpheaform, and fibroepithelial. BCC's molecular basis includes inherited genetic susceptibility and somatic mutations, often induced by exposure to UV radiation. The aberrant activation of the hedgehog (Hh) signalling pathway, caused by mutations in the Hh components, plays a central role in the molecular pathogenesis of this carcinoma. This led to the development of Hh signalling pathway inhibitors as a new treatment option for patients with advanced disease. In this review, we summarise BCC's clinical presentation and histopathology and present knowledge on the most studied Hh signalling inhibitors, vismodegib and sonidegib, and other inhibitors of this signalling, such as itraconazole, patidegib, taladegib, and arsenic trioxide, in the treatment of BCC. We also present the most common Hh signalling inhibitor adverse events and their management options, which could improve patients' quality of life during treatment.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1322-1342"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the role of ethosomes in rheumatoid arthritis: innovative solutions to challenges in transdermal delivery of synthetic drugs and phytoconstituents. 了解类风湿性关节炎中溶酶体的作用：合成药物和植物成分经皮递送挑战的创新解决方案。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-04-11 DOI: 10.1080/1061186X.2025.2477068

Rohan Anchan, Anish Ghadi, Mohammed Ali Chauhan, Angel Godad, Sankalp Gharat

{"title":"Understanding the role of ethosomes in rheumatoid arthritis: innovative solutions to challenges in transdermal delivery of synthetic drugs and phytoconstituents.","authors":"Rohan Anchan, Anish Ghadi, Mohammed Ali Chauhan, Angel Godad, Sankalp Gharat","doi":"10.1080/1061186X.2025.2477068","DOIUrl":"10.1080/1061186X.2025.2477068","url":null,"abstract":"Rheumatoid Arthritis (RA), an autoimmune disease, is a chronic inflammatory disorder affecting the joints leading to severe damage and cartilage destruction. Current therapies for RA such as DMARDs, NSAIDs, glucocorticoids and phytoconstituents often face challenges related to solubility and transdermal permeability. Considering the barriers posed by the stratum corneum in transdermal drug delivery, ethosomes have shown promising results in overcoming these hurdles. The presence of ethanol in ethosomes imparts flexibility and disrupts the skin's lipid bilayer, allowing for transdermal penetration. Researchers have explored the potential of ethosomal drug delivery systems loaded with various synthetic drugs and phytoconstituents for the management of RA. Despite promising preclinical findings, these systems have yet to transition from the bench to the bedside, and there is a lack of comprehensive review papers highlighting the potential of ethosomes in RA treatment. Considering the commercial challenges in scaling up such nano systems, this review aims to analyse the current state of the art and advancements in ethosomal formulations loaded with synthetic agents and phytoconstituents. Further, it explores the impact of excipients and processing parameters, on the preparation of ethosomes and their efficacy in overcoming skin barriers, to enhance the permeability of therapeutic agents.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1247-1261"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methodological advances in liposomal encapsulation efficiency determination: systematic review and analysis. 脂质体包封效率测定的方法学进展：系统回顾与分析。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-03-31 DOI: 10.1080/1061186X.2025.2484773

Jin-Ping Wang, Zi-Rui Huang, Cheng Zhang, Yi-Ran Ni, Bo-Tao Li, Ying Wang, Jiang-Feng Wu

{"title":"Methodological advances in liposomal encapsulation efficiency determination: systematic review and analysis.","authors":"Jin-Ping Wang, Zi-Rui Huang, Cheng Zhang, Yi-Ran Ni, Bo-Tao Li, Ying Wang, Jiang-Feng Wu","doi":"10.1080/1061186X.2025.2484773","DOIUrl":"10.1080/1061186X.2025.2484773","url":null,"abstract":"Liposomes represent a highly promising drug delivery platform for a wide range of pharmaceutical compounds. Encapsulation efficiency (EE) stands as a critical quality attribute for liposomal formulations. Accurate determination of EE requires quantification of at least two parameters among the three distinct drug populations: total drug content, encapsulated drug fraction, and free drug concentration. However, due to the complex physicochemical characteristics of liposomes, particularly their structural flexibility, surface charge properties, and organic phase composition, direct measurement of encapsulated and free drug fractions presents significant analytical challenges. The ability to precisely quantify both free and total drug concentrations in liposomal formulations enables rapid and reliable evaluation of encapsulation efficiency, which is essential for guiding formulation optimisation and ensuring consistent product quality during scale-up manufacturing processes. This review provides a comprehensive analysis of various analytical techniques for EE determination, including (reverse) dialysis, ultrafiltration centrifugation, differential centrifugation (ultra/low-speed), and size exclusion chromatography, with particular emphasis on their methodological characteristics, applicable ranges, advantages, and limitations. Furthermore, we propose appropriate detection strategies for encapsulation efficiency assessment based on specific laboratory capabilities and the physicochemical properties of the investigational compounds.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1262-1271"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast cancer cell targeting of L-leucine-PLGA conjugated hybrid solid lipid nanoparticles of betulin via L-amino acid transport system-1. l -氨基酸转运系统靶向l -亮氨酸- plga偶联白桦素固体脂质纳米颗粒的乳腺癌细胞

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-05-14 DOI: 10.1080/1061186X.2025.2500036

Shilpa Amit Gajbhiye, Moreshwar P Patil

{"title":"Breast cancer cell targeting of L-leucine-PLGA conjugated hybrid solid lipid nanoparticles of betulin via L-amino acid transport system-1.","authors":"Shilpa Amit Gajbhiye, Moreshwar P Patil","doi":"10.1080/1061186X.2025.2500036","DOIUrl":"10.1080/1061186X.2025.2500036","url":null,"abstract":"The aim of fabricating hybrid solid lipid nanoparticles (HSLN) was to enhance the delivery of betulin to triple negative breast cancer cells through the intravenous route via L-amino transporter system-1, using L-leucine-PLGA conjugate (Conj-HSLN) by hot high pressure homogenisation method. Betulin (BN), having potent anticancer and antioxidant activity, faces challenges due to poor water solubility and permeability, affecting its bioavailability. The results revealed Conj-HSLN with particle size 318.3 ± 0.25 nm. The percent cumulative BN release from Conj-HSLN was 57.763%, 24h. The cytotoxicity study in MB-MDA-231 cell depicts, LD50 67.73 µg/ml in Conj-HSLN. Pharmacokinetics study reveals enhanced Cmax and half-life in Conj-HSLN (32.12 ± 0.25 µg/ml, 4.72 ± 0.53 h) than raw BN (1.31 ± 0.21 µg/ml, 7.54 ± 0.34 h). Enhanced distribution at tumour site (11.5967% ID, 2h) in Conj-HSLN signifies the role of L-leucine in the transport system. Pharmacodynamic study shows mean tumour volume of 765.3 ± 85.884, and 1450.01 ± 219.361 mm3 in Conj-HSLN, and BN, respectively, at 3rd week of treatment. Standardised uptake value attributed reduced glucose uptake, due to inhibited tumour growth and proliferation, confirmed by tumour biomarkers assay, VEGF and Caspase-9. In conclusion, the targeted controlled release L-leucine conjugated-BN loaded HSLN is stable, safe, and effective against triple negative breast cancers.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1432-1461"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emodin nanocrystals enhanced mucus penetration and ameliorated bleomycin-induced pulmonary fibrosis by pulmonary delivery. 大黄素纳米晶体通过肺输送增强黏液渗透并改善博来霉素诱导的肺纤维化。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-09-01 Epub Date: 2025-04-30 DOI: 10.1080/1061186X.2025.2497369

Chenghao Zhang, Yihua Wang, Xinran Cui, Qing Zhang, Huijing Cong, Jiaxin Liu, Jinmei Ren, Jingling Tang

{"title":"Emodin nanocrystals enhanced mucus penetration and ameliorated bleomycin-induced pulmonary fibrosis by pulmonary delivery.","authors":"Chenghao Zhang, Yihua Wang, Xinran Cui, Qing Zhang, Huijing Cong, Jiaxin Liu, Jinmei Ren, Jingling Tang","doi":"10.1080/1061186X.2025.2497369","DOIUrl":"10.1080/1061186X.2025.2497369","url":null,"abstract":"Pulmonary fibrosis (PF) is a progressive interstitial disease characterised by extracellular matrix deposition and destruction of lung tissue structure. Emodin (Emo) is a natural active compound with anti-inflammatory and antioxidant properties. The initiation of PF is prevented by reducing oxidative stress-induced damage to alveolar epithelial cells.\" to meet the word count requirement. However, Emo is featured low water solubility, a rapid metabolic rate and low oral bioavailability, which limit its application in the treatment of PF. Therefore, this study formulated emodin as nanocrystals (Emo-NCs) and delivered Emo directly to the lesion site via pulmonary delivery to enhance drug efficacy. The Emo-NCs exhibited a square crystal structure with particle sizes suitable for pulmonary absorption and an appropriate polydispersity index. They released 99.38% over 48 h and significantly improved permeability efficiency in simulated pulmonary mucus. The ability of Emo-NCs to inhibit abnormal fibroblast proliferation and oxidative damage was significantly enhanced compared with Emo. In contrast to the BLM group, the inflammatory cells in the lung tissue sections of the Emo-NCs group were significantly reduced, the alveolar structure was largely restored, and no evident collagen fibre deposition was observed. In summary, Emo-NCs could serve as a viable delivery system for site-specific treatment of PF.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1421-1431"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted delivery of anti-microRNA-21 oligonucleotides using chlorotoxin-engineered extracellular vesicles for treatment of glioblastoma. 利用氯毒素工程细胞外囊泡靶向递送抗microrna -21寡核苷酸治疗胶质母细胞瘤。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-27 DOI: 10.1080/1061186X.2025.2550594

Subin Kang, Mincheol Son, Minji Kang, Jae Young Park, Kangmin Park, Minhyung Lee

{"title":"Targeted delivery of anti-microRNA-21 oligonucleotides using chlorotoxin-engineered extracellular vesicles for treatment of glioblastoma.","authors":"Subin Kang, Mincheol Son, Minji Kang, Jae Young Park, Kangmin Park, Minhyung Lee","doi":"10.1080/1061186X.2025.2550594","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2550594","url":null,"abstract":"Glioblastoma is a devastating disease with a high mortality rate. Gene therapy with anti-microRNA inhibitors has been suggested as a new modality for treatment of glioblastoma. In this study, glioblastoma-targeted extracellular vesicles (EVs) were produced with specific ligands and evaluated as a carrier of anti-microRNA-21 oligonucleotides (AMO21). Angiopep-2 (ANG) and chlorotoxin (CTX) were linked to EVs by DNA recombination techniques. Cholesterol-conjugated AMO21 (AMO21c) was loaded onto the EVs decorated with ANG or CTX (ANG-EV or CTX-EV) by hydrophobic interactions. In vitro cellular uptake assays indicated that CTX-EV had higher delivery efficiency than unmodified EV (Unmod-EV) and ANG-EV. In addition, CTX-EV had higher transcytosis efficiency than the other EVs, suggesting that it effectively passes through the blood-brain barrier. In orthotopic glioblastoma animal models, CTX-EV delivered AMO21c more efficiently than Lipofectamine/AMO21c, Unmod-EV/AMO21c and ANG-EV/AMO21c. As a result, a greater decrease in tumour size with CTX-EV/AMO21c was observed, as compared with Lipofectamine/AMO21c, Unmod-EV/AMO21c and ANG-EV/AMO21c. CTX-EV/AMO21c induced the expression of the phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4) genes in tumours. In addition, apoptosis levels in tumour tissues were enhanced by CTX-EV/AMO21c, as compared with the other samples. In conclusion, CTX-EV is effective for targeted delivery of AMO21 to glioblastoma and may have potential in glioblastoma gene therapy.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-11"},"PeriodicalIF":3.9,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design, optimisation and in vivo evaluation of tazarotene loaded emulgel formulation for the treatment of acne. 他沙罗汀治疗痤疮乳状剂的设计、优化及体内评价。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-22 DOI: 10.1080/1061186X.2025.2546489

Amit Pratap Singh, Sushil Kumar Kashaw, Vandana Soni

{"title":"Design, optimisation and in vivo evaluation of tazarotene loaded emulgel formulation for the treatment of acne.","authors":"Amit Pratap Singh, Sushil Kumar Kashaw, Vandana Soni","doi":"10.1080/1061186X.2025.2546489","DOIUrl":"10.1080/1061186X.2025.2546489","url":null,"abstract":"Acne vulgaris is a common dermatological disorder, with current treatments often limited to poor skin penetration, instability, irritation and suboptimal therapeutic outcomes. There is a pressing need for advanced drug delivery systems that can overcome these limitations and enhance treatment efficacy. This study aimed to develop and optimise a novel tazarotene-loaded emulgel formulation, combining the advantages of emulsions and gels to achieve controlled drug release, improved stability and superior clinical performance in topical acne therapy. The formulation was prepared using the incorporation method and optimised through the Box-Behnken statistical design (BBD). Three independent variables, such as Carbopol 940 (X1), Span 80 (X2) and Tween 80 (X3), were assessed for their effects on drug release (Y1) and viscosity (Y2). The optimised formulation exhibited desirable characteristics, including pH: 6.6 ± 0.3, viscosity: 28,945 cPs, spreadability: 6.17 ± 0.02 cm2, extrudability: 18 ± 2.49 g/cm2 and drug content: 85.46 ± 4.02%. In vitro studies demonstrated 87.59 ± 2.6% drug release over 7 h. A skin irritation test in mice confirmed its dermatological safety, with no signs of erythema or oedema. Anti-acne efficacy, evaluated using a Propionibacterium acnes-induced murine model, revealed complete lesion clearance, outperforming a marketed gel. These findings firmly establish the tazarotene-loaded emulgel as a safe, effective, and superior topical treatment for acne.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-9"},"PeriodicalIF":3.9,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-Omics approaches in gene therapy for vascular diseases: bridging genomics, transcriptomics, and epigenetics. 血管疾病基因治疗中的多组学方法：连接基因组学、转录组学和表观遗传学。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-22 DOI: 10.1080/1061186X.2025.2544786

Jianxin Dong, Ming Sun, Yanmei Li, Zhilei Xie

{"title":"Multi-Omics approaches in gene therapy for vascular diseases: bridging genomics, transcriptomics, and epigenetics.","authors":"Jianxin Dong, Ming Sun, Yanmei Li, Zhilei Xie","doi":"10.1080/1061186X.2025.2544786","DOIUrl":"10.1080/1061186X.2025.2544786","url":null,"abstract":"Vascular diseases such as atherosclerosis, aneurysms, and peripheral arterial disease remain leading causes of morbidity and mortality, with current treatments primarily managing symptoms rather than addressing underlying molecular drivers. Gene therapy offers a promising avenue for targeted intervention, and recent advances in multi-omics approaches-including genomics, transcriptomics, and epigenetics-are enhancing the precision and efficacy of these therapies. High-throughput sequencing and integrative omics analyses have facilitated the identification of causal genes, non-coding RNAs, and epigenetic regulators involved in vascular pathology. This review examines how multi-omics frameworks inform gene therapy design, from genomic editing of cardiovascular disease loci to transcriptome-guided RNA therapies and epigenetic modulation of disease states. We highlight emerging applications such as CRISPR-based interventions, RNA therapeutics, and individualised precision medicine strategies. Additionally, we address analytical challenges, implementation hurdles, and ethical considerations in translating multi-omics-driven gene therapies into clinical practice. By integrating systems biology and advanced computational methods, the convergence of multi-omics and gene therapy holds transformative potential for vascular medicine, offering new avenues for disease modification and patient-specific therapeutic solutions.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-16"},"PeriodicalIF":3.9,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0